๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cancer
Clinical trial register · China

Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 17 Guangzhou 15 Shanghai 12 Hangzhou 6 Nanjing 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking University Cancer Hospital & Institute4 Cancer Institute and Hospital, Chinese Academy of Medical Sciences4 Fudan University3 First Hospital of China Medical University2 Second Affiliated Hospital of Guangzhou Medical University2
Site location
Beijing17 Guangzhou15 Shanghai12 Hangzhou6 Nanjing6
All 37 locations
Target enrolment
to

Cancer trials in China

77 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Immunotherapy Treating GI Cancer
NCT03614650Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Recruiting
Real-World Study of Young Patients With Solid Tumors in China
NCT07708935Cancer
Fudan University
Observational
12,000
Shanghai
2026-07-31
Recruiting
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
NCT07724535Cancer
Peking University Cancer Hospital & Institute
Phase 1/2
30
Beijing
2026-06-24
Recruiting
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
NCT07752953Advanced Solid Tumor, Cancer, Malignant Solid Tumor
ZSky Biotech Inc
Not applicable
100
Qinhuangdao
2026-05-01
Not yet open
Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia
NCT07530666Cancer, Cachexia
Dartsbio Pharmaceuticals Ltd.
Phase 1/2
58
Guangzhou
2026-04-30
Not yet open
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
NCT07041788Cancer
DrugIparomlimab and Tuvonralimab
Second Affiliated Hospital of Nanchang University
Phase 2
25
Nanchang
2026-04-28
Recruiting
Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors
NCT07560943Cancer
West China Hospital
Phase 1
9
Chengdu
2026-04-28
Not yet open
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
NCT07562815Cancer
West China Hospital
Phase 1
9
Chengdu
2026-04-28
Active, closed
Development and Validation of an AI Foundation Model for Frozen-Section Pathology
NCT07708207Cancer, Intraoperative Pathology, Artificial Intelligence (AI)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
33,000
Guangzhou
2026-04-27
Recruiting
DXP-106 in Solid Tumor Patients.
NCT07532018Solid Tumor, Cancer
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
Phase 1
54
Harbin, Shanghai, Taiyuan, Hangzhou
2026-03-23
Recruiting
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors
NCT07410676Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
DrugPembrolizumab
Essen Biotech
Phase 1/2
83
Beijing
2026-02-01
Recruiting
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
NCT07410494Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
Essen Biotech
Phase 1/2
85
Beijing
2026-02-01
Recruiting
Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors
NCT07450872Cancer, Glioma, Leukemia (Both ALL and AML)
The Children's Hospital of Zhejiang University School of Medicine
Observational
600
Hangzhou
2026-01-01
Recruiting
A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors
NCT07538648Cancer
Zhejiang Cancer Hospital
Phase 1
400
Hangzhou
2025-12-24
By invitation
Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors
NCT07656090Cancer
DrugIDOV-Immune
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
19
Beijing
2025-12-18
Recruiting
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
NCT07269899Solid Tumor Cancer, Cancer
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Recruiting
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
NCT07702162Advanced Solid Tumors, Cancer
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
49
Fuzhou, Shanghai
2025-11-14
Recruiting
A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors
NCT06953453Cancer
Lee's Pharmaceutical Limited
Phase 1
100
Zhengzhou, Shanghai
2025-09-23
Not yet open
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
NCT07198321Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
DrugGFH276
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
450
Guangzhou
2025-09-22
Recruiting
Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies
NCT07058454Cancer;Cardiovascular;Adverse Events, Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
5,000
Guangzhou
2025-09-01
Recruiting
Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
NCT07110090Thrombocytopenia, Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
16
Beijing
2025-08-28
Not yet open
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
NCT07128277Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
10
Chongqing
2025-08-13
Recruiting
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748Cancer
Peking Union Medical College Hospital
Not applicable
120
Beijing
2025-08-01
Recruiting
Electroacupuncture on Treating Cancer-related Depression
NCT07003763Depression, Cancer
Shanghai Municipal Hospital of Traditional Chinese Medicine
Not applicable
86
Shanghai
2025-07-01
Recruiting
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
NCT06936748Cancer
Second Affiliated Hospital of Nanchang University
Phase 2
30
Nanchang
2025-06-20
Active, closed
Phase I PK Comparison of HLX05 vs. Erbituxยฎ in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
NCT06980454Cancer, mCRC
Shanghai Henlius Biotech
Phase 1
322
Xuzhou, Jiangsu
2025-06-04
Recruiting
PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors
NCT07383857Cancer
Zhen Zhang
Not applicable
103
Shanghai
2025-05-01
Not yet open
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy
NCT06716788Cancer
Peking University Cancer Hospital & Institute
Observational
50
Beijing
2025-05-01
Recruiting
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
NCT06858709Chemotherapy-induced Peripheral Neuropathy (CIPN), Cancer
Zhongnan Hospital
Not applicable
150
Wuhan
2025-03-20
Not yet open
Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy
NCT06891521Cancer, Adverse Events
Qinghai Red Cross Hospital
Phase 2
123
Xining
2025-03-20
Recruiting
Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
NCT06859190Cancer, Insomnia
Qinghai Red Cross Hospital
Phase 3
60
Xining
2025-03-01
Recruiting
Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue
NCT07656324Cancer
Fudan University
Observational
1,000,000
Shanghai
2025-01-17
Not yet open
EGFR Mutation Targeting Molecular Probe for PET Imaging
NCT06641674Cancer
Peking University Cancer Hospital & Institute
Observational
20
Beijing
2024-11-15
Recruiting
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
NCT06819215Cancer, Neoplasms, Neoplasms, Breast, Tumor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1/2
188
Jinan
2024-10-30
Not yet open
Multi-Disciplinary Treatment on the Anthropomorphism of Large Language Models
NCT06627985Cancer, Respiratory Failure, Heart Diseases, Infections
North Sichuan Medical College
Observational
300
Nanchong
2024-10-01
Recruiting
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
NCT06495515CANCER, BRAEST CANCER, Late Frontline
Tianjin Medical University Cancer Institute and Hospital
Phase 2
36
Tianjin
2024-08-01
Recruiting
Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis
NCT06517979Cancer, Lymphatic Metastasis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
10,000
Guangzhou
2024-07-26
Recruiting
Nutrition Impact on Immunotherapy of Cancer
NCT06500234Nutrition Disorders, Immunotherapy, Cancer, Survival, Prosthesis
Qingdao Central Hospital
Phase 3
300
Qingdao
2024-06-01
Recruiting
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
NCT06419361Stimulator of Interferon Gene, Cancer, Positron Emission Tomography
First Affiliated Hospital of Chongqing Medical University
Phase EARLY_PHASE1
30
Chongqing
2024-05-30
Recruiting
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
NCT06612632Cancer
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
100
Beijing
2024-05-24
Recruiting
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours
NCT06430502Cancer, PD-L1 Gene Mutation
Wuxi People's Hospital
Not applicable
200
Wuxi
2024-05-07
Active, closed
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
NCT07059832Cancer
Drug68Ga-NODAGA-SNA006
First Hospital of China Medical University
Phase 1/2
30
Shenyang
2024-04-01
Recruiting
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
NCT06203119Cancer
Drug18F-FDG
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2024-03-06
Recruiting
Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)
NCT06930586Cancer, Brain Injury
The First Affiliated Hospital of Zhengzhou University
Observational
213
Henan
2024-03-01
Recruiting
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590Cancer, FAP
Hunan Cancer Hospital
Observational
500
Changsha
2024-01-01
Recruiting
Application of FAPI and FDG PET Imaging in Patients With Different Types of Cancer
NCT06284070Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
2,000
Chongqing
2024-01-01
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
A Study of TAVO412 in Patients with Cancer (TAVO412)
NCT06761651Cancer
DrugTAVO412
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Not yet open
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06149533Thrombosis, Venous, Cancer, Catheter Complications
DrugEdoxaban
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Recruiting
Nutritional Intervention for Patients With Multiple Cancer Types
NCT06059560Cancer
First Hospital of China Medical University
Not applicable
1,000
Shenyang
2023-10-01
Recruiting
Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
NCT06360471Fertility Issues, Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
2,800
Nanjing
2023-10-01
Recruiting
The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors
NCT06430515Intratumoral Injection, Cancer
Wuxi People's Hospital
Not applicable
200
Wuxi
2023-09-01
Recruiting
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028Cancer, Solid Malignancies
Affiliated Hospital of Jiangnan University
Not applicable
30
Wuxi
2023-07-12
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
DrugsIpatasertib·Tiragolumab·Divarasib·Entrectinib
Hoffmann-La Roche
Phase 3
100
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
NCT05629234Cancer
DrugOsimertinib
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Recruiting
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
NCT05556603Cancer
Ruijin Hospital
Observational
7,062
Shanghai
2022-12-28
Recruiting
The Jinling Cohort
NCT06011694Cancer, Multi Cancer Early Screening, Liquid Biopsy
Nanjing Shihejiyin Technology, Inc.
Observational
15,000
Nanjing
2022-06-15
Recruiting
The Dampness Syndrome of Chinese Medicine Cohort Study
NCT05315895Chronic Disease, Cancer, Dementia Alzheimers, Metabolic Disease
Guangzhou University of Traditional Chinese Medicine
Observational
100,000
Guangzhou
2022-06-06
Recruiting
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
NCT05227534Cancer, Early Detection of Cancer, Circulating Cell-free DNA
Guangzhou Burning Rock Dx Co., Ltd.
Not applicable
12,500
Chengdu
2022-06-01
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
DrugDurvalumab
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Recruiting
Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
NCT05347524Cancer
Shanghai Zhongshan Hospital
Observational
384
Shanghai
2022-03-01
Recruiting
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
NCT05141253Cancer
Tongji Hospital
Phase EARLY_PHASE1
24
Wuhan
2022-01-12
Active, closed
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST
NCT06979921Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
496
Nanjing, Qingdao
2021-07-10
Active, closed
The Kunshan Elderly Health Study
NCT05141565Cardiovascular Diseases, Diabetes Mellitus, Cancer, Cognitive Impairment
Soochow University
Observational
5,945
Kunshan
2021-05-17
Recruiting
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
NCT04721041Intestinal Complications, Cancer
The Second Hospital of Nanjing Medical University
Not applicable
200
Nanjing
2021-01-26
Recruiting
Antineoplastic Drugs in Elderly Patients
NCT05467189Cancer
DrugsLapatinib·Ceritinib·Busulfan·Afatinib
Shandong University
Observational
500
Jinan
2021-01-01
Recruiting
Nutritional Status and Clinical Outcomes in Patients With Common Malignancies(NCOM)
NCT06219083Cancer, Chemoradiotherapy, Nutrition, Healthy, Oncology
Xiaoqin Luo
Observational
1,538
Xi'an
2020-11-12
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Recruiting
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
NCT04766515Cancer
Fudan University
Observational
6,000
Shanghai
2020-09-01
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Relatlimab·Sunitinib·Cabozantinib
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Recruiting
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients
NCT05061342Cancer
Fengming Kong
Observational
5,000
Shenzhen
2019-06-27
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Active, closed
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
DrugsABBV-181·ABBV-927·Nab-paclitaxel·Carboplatin
AbbVie
Phase 1
150
2019-05-21
Active, closed
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418Cancer
DrugsAtezolizumab·Bevacizumab
Hoffmann-La Roche
Phase 3
382
2017-09-20
Recruiting
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
NCT03192501Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer
Second Affiliated Hospital of Guangzhou Medical University
Observational
250
Guangzhou
2017-07-01
Recruiting
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
NCT03198052Lung Cancer, Cancer, Immunotherapy, CAR-T Cell
DrugEGFR
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
Epstein-Barr Virus and Cancer Risks
NCT06203314Cancer
Sun Yat-sen University
Observational
100,000
Zhongshan, Wuzhou
2008-08-01
Rows per page Showing 1–77 of 77
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 77 of those studies listing the condition Cancer.

How many Cancer trials are recruiting in China?

55 of the 77 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 11 have not yet opened recruitment, 9 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cancer), 77 studies
PhaseStudiesRecruitingShare
Observational282136.4%
Phase 1131016.9%
Not applicable111114.3%
Phase 1/29511.7%
Phase 38310.4%
Phase 2536.5%
Phase EARLY_PHASE1323.9%

Most active sponsors

Lead sponsors with the most studies (Cancer)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences42
Peking University Cancer Hospital & Institute42
Fudan University33
AstraZeneca20
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University21
Essen Biotech22
First Hospital of China Medical University21
Hoffmann-La Roche21
Qinghai Red Cross Hospital21
Second Affiliated Hospital of Guangzhou Medical University22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.